{"id":"W3015065138","doi":"10.1007/s13555-020-00373-z","title":"Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence","year":2020,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Biotech; Sanofi Genzyme; AstraZeneca; Allergan; Ortho Dermatologics; LEO Pharma; National Psoriasis Foundation; Pfizer; Biogen; Incyte; Regeneron Pharmaceuticals; Mylan; Castle Biosciences; Novartis Pharmaceuticals Corporation; Dermira; Sun Pharma; Celgene; Sanofi; Galderma; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Genentech; Valeant Pharmaceuticals International; Amgen","keywords":"Secukinumab; Medicine; Disease; Intensive care medicine; Psoriasis; Psoriatic arthritis; Clinical trial; Immunology; Dermatology; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007513914,0.0004141984,0.002290687,0.0001110091,0.00007763747,0.000002550944,0.0002181091,0.0003512077,0.0001394615],"category_scores_gemma":[0.00002373093,0.000214652,0.000325589,0.0003184584,0.0002156785,0.00004033622,0.00004268847,0.0001601205,0.00002894961],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004323792,"about_ca_system_score_gemma":0.0002340179,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000498011,"about_ca_topic_score_gemma":0.00001334205,"domain_scores_codex":[0.997853,0.0007957158,0.000678047,0.0003833846,0.00004418675,0.0002456699],"domain_scores_gemma":[0.9985123,0.0003866031,0.0006044143,0.0004353987,0.00004270763,0.00001860504],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001522949,0.000228578,0.0003445783,0.01429991,0.001136557,0.0000478796,0.000633004,6.597876e-8,0.000008610054,0.00009001682,0.00009932943,0.9829592],"study_design_scores_gemma":[0.001367915,0.0005480674,0.00002752656,0.05234702,0.0008348861,0.0009895546,0.00003926846,2.516214e-7,0.0005444487,0.000007453204,0.9430804,0.0002132139],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001013759,0.997149,7.034439e-7,0.0002463791,0.0001949266,0.001207614,0.00005235106,0.00001288209,0.0001224155],"genre_scores_gemma":[0.002669576,0.9968738,0.00001475881,0.00007418008,0.000008436411,0.0002486074,0.00003865193,0.00002299536,0.00004897729],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9827459,"threshold_uncertainty_score":0.8753254,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04918913432521317,"score_gpt":0.2794191380912929,"score_spread":0.2302300037660797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}